Ipsen Biotech Sas Patent-Cliff Exposure & CMS Drug Spending Portfolio
Ipsen Biotech Sas (US): 1 reconciled FDA prescription therapies, $90.9M 2024 CMS Part D & Medicaid spend, and $9,460 CA SB 17 specialty launch WAC.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Headquarters / Cluster | US |
| Reconciled FDA Portfolio Therapies | 1 |
| 2025 to 2030 Patent-Cliff Revenue Exposure | 0.0% |
| Primary Portfolio LOE Date | Multi-asset schedule |
| 2024 CMS Total Public Spend | $90.9M |
| 2024 Medicare Part D Spend | $57.7M |
| 2024 Medicaid Spend | $33.2M |
| California HCAI SB 17 Filings | Specialty launch notice ($9,460 intro WAC) |